Table 3.
Concentrations of annexin V non-binding (AnxV−) MP subsets stratified by the presence of selected disease manifestation of systemic sclerosis (SSc)
| Clinical Variable | AnxV− EMPs | AnxV− LMPs | AnxV− PMPs | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (MP x 105) | (MP x 104) | (MP x 105) | |||||||||||||
| Symptom | No symptom | P | Symptom | No symptom | p | Symptom | No symptom | p | |||||||
| Mean | ± SD | Mean | ± SD | Mean | ± SD | Mean | ± SD | Mean | ± SD | Mean | ± SD | ||||
| Skin | |||||||||||||||
| Cutaneous ulcer | 8.01 | ±6.83 | 11.48 | ±16.11 | 0.64 | 9.47 | ±8.80 | 5.73 | ±31.49 | 0.84 | 4.59 | ±3.92 | 5.79 | ±7.88 | 0.66 |
| Calcinosis | 10.75 | ±9.71 | 9.16 | ±13.68 | 0.04 | 14.04 | ±18.78 | 14.59 | ±33.08 | 0.07 | 6.87 | ±10.39 | 4.41 | ±4.46 | 0.17 |
| Heart | |||||||||||||||
| SPAP > 40 | 18.46 | ±28.31 | 10.13 | ±13.10 | 0.63 | 24.64 | ±37.96 | 14.29 | ±27.95 | 0.96 | 4.63 | ±4.84 | 5.64 | ±7.54 | 0.43 |
| Lung | |||||||||||||||
| Fibrosis (among all) | 18.06 | ±22.91 | 9.30 | ±12.26 | 0.02 | 23.67 | ±35.67 | 13.35 | ±27.08 | 0.14 | 5.29 | ±4.82 | 5.62 | ±7.79 | 0.83 |
| Fibrosis (among dcSSc) | 22.13 | ±28.29 | 9.43 | ±12.36 | 0.02 | 28.14 | ±39.47 | 13.46 | ±27.34 | 0.13 | 7.19 | ±6.97 | 5.49 | ±7.80 | 0.54 |
| Fibrosis (among lcSSc) | 16.03 | ±20.61 | 9.43 | ±12.36 | 0.12 | 21.44 | ±34.96 | 13.46 | ±27.34 | 0.40 | 4.34 | ±3.23 | 5.49 | ±7.80 | 0.87 |
Student's t test: significance level: p < 0.05 in bold
mRSS: modified Rodnan skin score. SPAP: Systolic pulmonary arterial pressure. dcSSc; diffuse cutaneous SSc. lcSSc: limited cutaneous SSc